As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib

Table 3

Univariate analyses of baseline characteristics for overall survival.

Variable	HR (95% CI)	value
Age, per 1 year increase	0.99 (0.98–1.00)	0.197
Gender (ref: female)	0.83 (0.57–1.22)	0.349
Etiology HBV/others (ref: HBV)	0.84 (0.57–1.25)	0.392
Child-pugh A/B (ref: B)	1.53 (0.78–2.99)	0.216
ECOG 0/≥1 (ref: score of 0)	2.54 (1.90–3.39)	<0.001
Previous treatments (ref: no)	0.89 (0.55–1.44)	0.628
Tumor size, per 1 cm increase	1.11 (1.07–1.15)	<0.001
No. of HCC nodules, per 1 lesion increase	1.14 (1.06–1.22)	<0.001
PVTT (ref: absent)	2.98 (2.18–4.07)	<0.001
EHS (ref: absent)	2.02 (1.48–2.75)	<0.001
Ascites (ref: absent)	1.95 (1.22–3.11)	0.005
AFP (ref: ≤400 ng/ml)	1.82 (1.37–2.41)	<0.001
Albumin, per 1 g/L increase	0.96 (0.93–0.99)	0.005
Total bilirubin, per 1 μmol/L increase	1.03 (1.02–1.05)	<0.001
ALT, per 1 U/L increase	1.00 (1.00–1.01)	0.832
AST, per 1 U/L increase	1.01 (1.00–1.01)	<0.001
INR, per 1% increase	1.00 (0.99–1.01)	0.600

Abbreviations: HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombus; EHS, extrahepatic spreading; AFP, alpha-fetoprotein; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase. INR, International normalized ratio.